DelMar Pharmaceuticals, Inc. – "Modernizing Medicines: DelMar’s Strategic Edge for VAL-083 in Oncology"

DelMar Pharmaceuticals (OTCQX:DMPI) today published a new blog post on The Chairman’s Blog, written by the Company’s Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
As quoted in the press release:

In his new blog, DelMar CEO Jeffrey Bacha explains how the Company is developing its lead drug candidate, VAL-083, for glioblastoma multiforme (GBM) by combining published preclinical and clinical data and a modern understanding of biologic pathways. Mr. Bacha describes how VAL-083 attacks brain tumors differently than current therapies and presents a potential new treatment paradigm for the majority of GBM patients who are underserved by current treatments.

DelMar Pharmaceuticals CEO, Jeffrey Bacha, stated:

DelMar has an exciting year in store in 2016, as we continue to build on the momentum of encouraging data with VAL-083 from our ongoing Phase II trial in refractory GBM and newly planned clinical studies in front-line GBM and NSCLC.”

Connect with DelMar Pharmaceuticals (OTCQX:DMPI) to receive an Investor Presentation